Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Long-Term Investments (2016 - 2024)

Marimed has reported Long-Term Investments over the past 10 years, most recently at $274000.0 for Q1 2024.

  • Quarterly Long-Term Investments changed N/A to $274000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $274000.0 through Mar 2024, changed N/A year-over-year, with the annual reading at $221000.0 for FY2023, N/A changed from the prior year.
  • Long-Term Investments was $274000.0 for Q1 2024 at Marimed, up from $221000.0 in the prior quarter.
  • Over five years, Long-Term Investments peaked at $2.5 million in Q1 2021 and troughed at $89000.0 in Q2 2023.
  • The 5-year median for Long-Term Investments is $1.0 million (2020), against an average of $997690.0.
  • Year-over-year, Long-Term Investments plummeted 97.1% in 2020 and then skyrocketed 103.84% in 2021.
  • A 5-year view of Long-Term Investments shows it stood at $1.2 million in 2020, then crashed by 78.47% to $251000.0 in 2021, then surged by 439.04% to $1.4 million in 2022, then crashed by 83.67% to $221000.0 in 2023, then increased by 23.98% to $274000.0 in 2024.
  • Per Business Quant, the three most recent readings for MRMD's Long-Term Investments are $274000.0 (Q1 2024), $221000.0 (Q4 2023), and $164000.0 (Q3 2023).